Intraperitoneal administration of interferon β in ovarian cancer patients

• Published in: Cancer Vol. 56; no. 2; pp. 294 - 301
• Main Authors: Rambaldi, Alessandro, Introna, Martino, Colotta, Francesco, Landolfo, Santo, Colombo, Nicoletta, Mangioni, Costantino, Mantovani, Alberto
• Format: Journal Article
• Language: English
• Published: New York Wiley Subscription Services, Inc., A Wiley Company 15.07.1985; Wiley-Liss
• Subjects: Adult; Antineoplastic agents; Ascites - etiology; Ascites - prevention & control; Ascitic Fluid - immunology; Ascitic Fluid - pathology; Biological and medical sciences; Cell Survival - drug effects; Cells, Cultured; Chemotherapy; Combined Modality Therapy; Female; Humans; Injections, Intraperitoneal; Interferon Type I - adverse effects; Interferon Type I - therapeutic use; Lymphocytes - immunology; Macrophages - immunology; Medical sciences; Ovarian Neoplasms - complications; Ovarian Neoplasms - pathology; Ovarian Neoplasms - therapy; Palliative Care; Peritonitis - etiology; Pharmacology. Drug treatments; Pilot Projects; Human; Antineoplastic agent; Ovary; Chemotherapy; Intraperitoneal administration; Immunotherapy; Beta interferon; Tumor; Woman

Eight patients with advanced ovarian carcinomas resistant to conventional chemotherapy were injected with interferon (IFN) β (3 × 106 U) intraperitoneally twice a week. Seven subjects had ascites. Side effects included abdominal pain, fever, and constipation, but no hematologic toxicity was observed...